The most widespread nondermatologic malignancy in men, prostate cancer afflicts one in six American males and kills one in 34. Growing public awareness, an aging population, and increased PSA screening has led to greater detection of early-stage disease. Among newly diagnosed cases, for example, the proportion with T3 or T4 disease fell from 19% to 4% between 1988 and 1998, and those with metastatic disease at presentation fell from 14% to 3%, according to a study by Peter Carroll, MD, and colleagues at the University of California in San Francisco Comprehensive Cancer Center (J Clin Oncol. 2005;23:8146-8151).